Literature DB >> 10573147

Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein.

Ze Chen1, Tomoki Yoshikawa1, Shin-Etsu Kadowaki1, Yukari Hagiwara1, Kazutoshi Matsuo1, Hideki Asanuma1, Chikara Aizawa2, Takeshi Kurata1, Shin-Ichi Tamura1.   

Abstract

Protection against influenza virus infection and antibody responses in mice vaccinated with plasmid DNAs encoding haemagglutinin (HA), neuraminidase (NA) and nucleoprotein (NP) were compared among BALB/c (H-2d), B10 (H-2b) and C3H (H-2k) mice. Mice were inoculated with each DNA construct twice, 3 weeks apart, at a dose of 1 microg per mouse by particle-mediated DNA transfer (gene gun) to the epidermis. They were challenged with a lethal dose of the homologous virus 7 days after the second vaccination. NA-DNA provided significant protection in all strains of mouse, whereas HA-DNA afforded significant protection only in BALB/c mice. The serum antibody titres against NA or HA molecules in BALB/c, C3H and B10 mice were high, intermediate and low, respectively. NP-DNA failed to provide protection in any strain of mouse, and elicited low titres of anti-NP antibodies. These results suggest that NA-DNA can be used as a vaccine component to provide effective protection against influenza virus infection in various strains of mouse.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10573147     DOI: 10.1099/0022-1317-80-10-2559

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  26 in total

1.  Biological and protective properties of immune sera directed to the influenza virus neuraminidase.

Authors:  Stefan J Halbherr; Thomas H Ludersdorfer; Meret Ricklin; Samira Locher; Marianne Berger Rentsch; Artur Summerfield; Gert Zimmer
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Mucosal and systemic immune responses induced by recombinant Lactobacillus spp. expressing the hemagglutinin of the avian influenza virus H5N1.

Authors:  Zhisheng Wang; Qinghua Yu; Junkai Gao; Qian Yang
Journal:  Clin Vaccine Immunol       Date:  2011-11-30

3.  The proteosomal degradation of fusion proteins cannot be predicted from the proteosome susceptibility of their individual components.

Authors:  Petr O Ilyinskii; Anatoli B Meriin; Vladimir L Gabai; Evgeny V Usachev; Alexei G Prilipov; Galini Thoidis; Alexander M Shneider
Journal:  Protein Sci       Date:  2008-04-14       Impact factor: 6.725

Review 4.  Development of universal influenza vaccines based on influenza virus M and NP genes.

Authors:  M Zheng; J Luo; Z Chen
Journal:  Infection       Date:  2013-11-01       Impact factor: 3.553

5.  Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore.

Authors:  Yuk-Fai Lau; Lay-Hoon Tang; David Chien Lye; Eng-Eong Ooi; Yee-Sin Leo
Journal:  Hum Vaccin Immunother       Date:  2017-02-17       Impact factor: 3.452

6.  Evaluation of antibody response in mice against avian influenza A (H5N1) strain neuraminidase expressed in yeast Pichia pastoris.

Authors:  Murugan Subathra; Ponsekaran Santhakumar; Mangamoori Lakshmi Narasu; Syed Sultan Beevi; Sunil K Lal
Journal:  J Biosci       Date:  2014-06       Impact factor: 1.826

Review 7.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

8.  Recombinant parainfluenza virus 5 expressing hemagglutinin of influenza A virus H5N1 protected mice against lethal highly pathogenic avian influenza virus H5N1 challenge.

Authors:  Zhuo Li; Alaina J Mooney; Jon D Gabbard; Xiudan Gao; Pei Xu; Ryan J Place; Robert J Hogan; S Mark Tompkins; Biao He
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

9.  Prime-boost vaccination with a combination of proteosome-degradable and wild-type forms of two influenza proteins leads to augmented CTL response.

Authors:  P O Ilyinskii; A B Meriin; V L Gabai; O P Zhirnov; G Thoidis; A M Shneider
Journal:  Vaccine       Date:  2008-03-14       Impact factor: 3.641

10.  Characterization of a neuraminidase-deficient influenza a virus as a potential gene delivery vector and a live vaccine.

Authors:  Kyoko Shinya; Yutaka Fujii; Hiroshi Ito; Toshihiro Ito; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.